DEA Puts Anti-Epileptic CBD Drug on Schedule V
A Historic Decision by the DEA On September 27, 2018, the US Drug Enforcement Agency (DEA) announced it was placing the childhood epilepsy drug, Epidiolex, on schedule V of the …
Johns Hopkins Scientists Recommend Rescheduling Psilocybin
Scientists at Johns Hopkins Medical School Recommend Rescheduling Psilocybin Since 1970, psilocybin has been categorized as a Schedule I drug by the U.S. Drug Enforcement Agency (DEA). Schedule I is …
Psilocybin Clinical Trials Approved by FDA
FDA Approves COMPASS Pathways’s Psilocybin Clinical Trials The United States Food and Drug Administration (FDA) has approved COMPASS Pathways’s clinical trials using psilocybin for treating depression, namely “Treatment Resistant Depression” …
Magic Mushrooms vs Cannabis – Entourage Effect
Entourage Effect – Synergistic Combinations of Active Ingredients Magic mushrooms contain multiple active ingredients, collectively called “psilocybin derivatives.” These molecules work together to create an “entourage” of psychoactive (and non-psychoactive) effects …
COMPASS Pathways – Access to Synthetic Psilocybin
COMPASS Pathways Targeting “Patient Access” to Synthetic Psilocybin COMPASS Pathways is a life sciences company, founded in 2016, to “accelerate patient access to evidence-based innovation in mental health.” According to their …
Psilocybin and the “Right to Try Act”
Psilocybin and the “Right to Try Act” On Wednesday, May 29th, 2018, President Donald Trump signed the “Right to Try Act,” a measure aimed at helping terminally ill patients access …
Psilocybin for Treating Phantom Pain
Read this article at Psychedelic Science Review
Microdosing – Unmet Need for Precise Dosing
Microdosing – Popular Trend Needing Greater Accuracy Recently, microdosing has been gaining popularity and attention. The term “microdosing” is typically used to describe taking a small amount of a “psychedelic” …
COMPASS Pathways is NOT “Giving Mushrooms to Depressed Patients”
COMPASS pathways is not giving mushrooms to depressed patients. The New York Post published an article titled, “Startup plans to give mushrooms to depressed patients.” The article is about COMPASS Pathways of London. …
Psilocybin for Treating Violent Behavior
Psilocybin as a Means of Curbing Violent Behavior ABSTRACT Within the last four years, two prominent psychology researchers published reports related to the effects of hallucinogens and their potential for …